KRAS and familial pancreatic carcinoma: More recent reports described the use of exosome-derived DNA, which arises from viable pancreatic cancer cells, demonstrating that increased occurrence of KRAS mutations in exosome-derived DNA was a predictor of progression-free survival and OS and correlated with disease progression [154,155].